SCHEDULE: Commodore Capital Discloses 7.1% Stake in Century Therapeutics

Commodore Capital LP and its affiliates have reported a 7.1% beneficial ownership stake in Century Therapeutics, Inc., including shares and warrants.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 13,043,478 shares of Century Therapeutics, Inc. Common Stock.
• This represents 7.1% of the company's outstanding Common Stock.
• The ownership includes 8,695,652 shares of Common Stock and 4,347,826 shares underlying a warrant of Century Therapeutics, Inc.
• The ownership percentage is calculated based on 179,337,686 shares of Common Stock outstanding on January 9, 2026, plus the shares acquirable upon the exercise of the warrants.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently drives strong positive or negative sentiment, beyond the general market interpretation of institutional investment.

Positives

• A significant institutional investor, Commodore Capital, has taken a 7.1% beneficial ownership stake in Century Therapeutics, which may be interpreted by the market as a signal of confidence in the company's long-term prospects.

Negatives

• The filing itself does not contain any explicitly negative information regarding Century Therapeutics, Inc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the significant stake by an institutional investor as a positive signal of confidence, potentially influencing market perception and share price.
• Company Management: Awareness of a significant passive institutional shareholder.

Key Dates

Keywords

Century Therapeutics, Commodore Capital, beneficial ownership, Schedule 13G, common stock, warrants, institutional investment, 15673T100